Courtney T. van Geelen
Research Subjects
Courtney T. van Geelen has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Sherene Loi
Division of Cancer Research Peter MacCallum Cancer Centre Melbourne Victoria Australia
12 shared publications - Peter Savas
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
11 shared publications - Prudence A. Francis
Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Breast Cancer Trials Australia & New Zealand, Newcastle, Australia; International Breast Cancer Study Group, a division of ETOP IBCSG Partners Foundation, Bern, Switzerland
11 shared publications - Chen-Fang Weng
Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia
8 shared publications - Sarah-Jane Dawson
Peter MacCallum Cancer Centre, Melbourne, Australia
8 shared publications - Stephen J. Luen
Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia
8 shared publications
Latest Publications
- 20 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
A randomised phase II trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy in ER-positive breast cancer (ANZ1401 ELIMINATE)
Purpose: Patients with large estrogen receptor (ER)-positive, HER2-negative breast cancers have low pathologic complete response (pCR) rates with neoadjuvant chemotherapy. We aimed to determine the rate of tumor downstaging with concurrent neoadjuvant chemo-endocrine therapy (CET) compared with neoadjuvant chemotherapy (CT) in clinical stage 2/3 breast cancer. Methods: This phase II trial randomized women with operable grade 2-3, ER+/HER2- tumors with a primary >20mm 2:1 to neoadjuvant chemotherapy plus concurrent letrozole, or chemotherapy alone. Primary outcome was proportion of tumors down-staged to ≤20mm and ypT0-1ypN0/stage 0-1A. Evaluation of tumor infiltrating lymphocytes (TILs), RNA and DNA sequencing were performed to identify correlates of response. Results: ELIMINATE randomized 134 women, with 122 evaluable for the primary outcome. 24% (19/81) with CET and 20% (8/41) with CT (difference 3.9%, 95% CI -11% to 19%) achieved downstaging to ypT0-1ypN0. Overall, 6/122 (5%) had a pCR, all in the CET arm. MRI response was seen in 79% (CET), 66% (CT). Considering grade 3 tumors, 5/22 (23%) in the CET arm and 0/10 in the CT arm achieved pCR. Translational analyses revealed that pCR and RCB 0–I responses were enriched in baseline tumors with higher grade, higher TILs, elevated TMB, and immune activation signatures, independently of treatment arm. Conclusion: CET did not significantly increase downstaging to stage 0-IA. Exploratory analyses suggest a subset of high-grade ER+/HER2- tumors enriched for immune activity, with elevated TILs and high TMB, were associated with favourable response irrespective of treatment assignment. These findings support further exploration of immune-genomic biomarkers in future studies of ER+/HER2- breast cancer.
- 20 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
A randomised phase II trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy in ER-positive breast cancer (ANZ1401 ELIMINATE)
Purpose: Patients with large estrogen receptor (ER)-positive, HER2-negative breast cancers have low pathologic complete response (pCR) rates with neoadjuvant chemotherapy. We aimed to determine the rate of tumor downstaging with concurrent neoadjuvant chemo-endocrine therapy (CET) compared with neoadjuvant chemotherapy (CT) in clinical stage 2/3 breast cancer. Methods: This phase II trial randomized women with operable grade 2-3, ER+/HER2- tumors with a primary >20mm 2:1 to neoadjuvant chemotherapy plus concurrent letrozole, or chemotherapy alone. Primary outcome was proportion of tumors down-staged to ≤20mm and ypT0-1ypN0/stage 0-1A. Evaluation of tumor infiltrating lymphocytes (TILs), RNA and DNA sequencing were performed to identify correlates of response. Results: ELIMINATE randomized 134 women, with 122 evaluable for the primary outcome. 24% (19/81) with CET and 20% (8/41) with CT (difference 3.9%, 95% CI -11% to 19%) achieved downstaging to ypT0-1ypN0. Overall, 6/122 (5%) had a pCR, all in the CET arm. MRI response was seen in 79% (CET), 66% (CT). Considering grade 3 tumors, 5/22 (23%) in the CET arm and 0/10 in the CT arm achieved pCR. Translational analyses revealed that pCR and RCB 0–I responses were enriched in baseline tumors with higher grade, higher TILs, elevated TMB, and immune activation signatures, independently of treatment arm. Conclusion: CET did not significantly increase downstaging to stage 0-IA. Exploratory analyses suggest a subset of high-grade ER+/HER2- tumors enriched for immune activity, with elevated TILs and high TMB, were associated with favourable response irrespective of treatment assignment. These findings support further exploration of immune-genomic biomarkers in future studies of ER+/HER2- breast cancer.
- Open Access
Timing of breast cancer diagnosis postpartum and survival in women with germline pathogenic variants
- Open Access
- 20 October 2025
- Published by Springer Nature in Nature
- Vol. 649 (8096) , 449-459
Parity and lactation induce T-cell-mediated breast cancer protection
Parity and breastfeeding reduce the risk of breast cancer, particularly triple-negative breast cancer (TNBC)1,2, yet the immunological mechanisms underlying this protection remain unclear. Here, we show that parity induces an accumulation of CD8+ T cells, including cells with a tissue-resident memory (TRM)-like phenotype within human normal breast tissue. In murine models, pregnancy followed by lactation and involution drove the accumulation of CD8⁺ T cells in the mammary gland, coinciding with reduced tumour growth and increased intratumoural immune cell infiltration, effects that were abrogated by CD8⁺ T cell depletion. Importantly, this CD8+ T cell dependent tumour control was only observed following a complete cycle of lactation and involution. Consistent with this, primary TNBCs from parous women exhibited greater T cell infiltration and improved clinical outcomes. Together these findings, spanning preclinical models and over 1000 patient samples, provide new insight into how reproductive history shapes breast immunity, positioning CD8⁺ T cells as key mediators of parity-associated protection and informing novel strategies for both prevention and treatment of breast cancer.
- 20 October 2025
- Published by Springer Nature in Nature
- Vol. 649 (8096) , 449-459
Open AccessParity and lactation induce T-cell-mediated breast cancer protection
Parity and breastfeeding reduce the risk of breast cancer, particularly triple-negative breast cancer (TNBC)1,2, yet the immunological mechanisms underlying this protection remain unclear. Here, we show that parity induces an accumulation of CD8+ T cells, including cells with a tissue-resident memory (TRM)-like phenotype within human normal breast tissue. In murine models, pregnancy followed by lactation and involution drove the accumulation of CD8⁺ T cells in the mammary gland, coinciding with reduced tumour growth and increased intratumoural immune cell infiltration, effects that were abrogated by CD8⁺ T cell depletion. Importantly, this CD8+ T cell dependent tumour control was only observed following a complete cycle of lactation and involution. Consistent with this, primary TNBCs from parous women exhibited greater T cell infiltration and improved clinical outcomes. Together these findings, spanning preclinical models and over 1000 patient samples, provide new insight into how reproductive history shapes breast immunity, positioning CD8⁺ T cells as key mediators of parity-associated protection and informing novel strategies for both prevention and treatment of breast cancer.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400599
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials
PURPOSE: To investigate whether hormone receptor–positive, human epidermal growth factor receptor 2–low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics. METHODS: This study included HR+, HER2-negative early breast cancers from patients enrolled in the phase III, randomized BIG 1-98 and SOFT clinical trials that had undergone tumor genomic sequencing. Tumors were classified HR+HER2-low if they had a centrally reviewed HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization and HR+HER2-zero if they had an HER2 IHC score of 0. RESULTS: A total of 1,795 tumors were evaluable for this study (BIG 1-98 n = 520, SOFT n = 1,275). The frequency of HER2-low tumors was 37% and 21% in the postmenopausal BIG 1-98 and premenopausal SOFT cohorts, respectively. There were no significant differences in clinicopathologic variables between HER2-low and HER2-zero groups which was consistent across both trials. There was no significant difference in risk of distant recurrence for patients with HER2-low tumors versus HER2-zero tumors (5-year % distant recurrence-free 94.0% v 92.8%, P = .61, in BIG 1-98; 89.4% v 92.7%, P = .31, in SOFT, respectively). Somatic genomic profiles were similar with the exception of MAP3K1 mutations which were more frequent in HER2-zero tumors (BIG 1-98 19% v 5%, SOFT 11% v 6%). Both ERBB2 copy number and ERBB2 gene expression abundance were significantly higher in HER2-low tumors compared with HER2-zero tumors; however, the absolute difference was small. Correlation between ERBB2 copy number values and gene expression was modest ( r = 0.17). CONCLUSION: In two large clinical trials with centrally reviewed HER2 IHC, our findings do not support HER2-low breast cancer as a distinct clinical or biologic entity among HR+HER2- early breast cancers. Absolute differences in median ERBB2 copy number levels or gene expression are small and of unclear biologic relevance.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400599
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials
PURPOSE: To investigate whether hormone receptor–positive, human epidermal growth factor receptor 2–low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics. METHODS: This study included HR+, HER2-negative early breast cancers from patients enrolled in the phase III, randomized BIG 1-98 and SOFT clinical trials that had undergone tumor genomic sequencing. Tumors were classified HR+HER2-low if they had a centrally reviewed HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization and HR+HER2-zero if they had an HER2 IHC score of 0. RESULTS: A total of 1,795 tumors were evaluable for this study (BIG 1-98 n = 520, SOFT n = 1,275). The frequency of HER2-low tumors was 37% and 21% in the postmenopausal BIG 1-98 and premenopausal SOFT cohorts, respectively. There were no significant differences in clinicopathologic variables between HER2-low and HER2-zero groups which was consistent across both trials. There was no significant difference in risk of distant recurrence for patients with HER2-low tumors versus HER2-zero tumors (5-year % distant recurrence-free 94.0% v 92.8%, P = .61, in BIG 1-98; 89.4% v 92.7%, P = .31, in SOFT, respectively). Somatic genomic profiles were similar with the exception of MAP3K1 mutations which were more frequent in HER2-zero tumors (BIG 1-98 19% v 5%, SOFT 11% v 6%). Both ERBB2 copy number and ERBB2 gene expression abundance were significantly higher in HER2-low tumors compared with HER2-zero tumors; however, the absolute difference was small. Correlation between ERBB2 copy number values and gene expression was modest ( r = 0.17). CONCLUSION: In two large clinical trials with centrally reviewed HER2 IHC, our findings do not support HER2-low breast cancer as a distinct clinical or biologic entity among HR+HER2- early breast cancers. Absolute differences in median ERBB2 copy number levels or gene expression are small and of unclear biologic relevance.
- Open Access
- 21 October 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-10
Sustained lymphocyte decreases after treatment for early breast cancer
The role of adaptive immunity in long-term outcomes in early breast cancer is increasingly recognised. Standard (neo)adjuvant chemotherapy can have adverse effects on immune cells. We conducted a retrospective longitudinal study of full blood counts (FBC) of 200 patients receiving (neo)adjuvant chemotherapy for early breast cancer at a single institution. FBC results at four time points from pre-treatment to 12 months post-chemotherapy were analysed. Flow cytometry was performed for patients with matched pre- and post-chemotherapy peripheral blood mononuclear cell samples. A significant decrease in absolute lymphocyte count at 12 months post-chemotherapy was observed (p < 0.01), most pronounced in pre-menopausal patients (n = 73; p < 0.01), patients receiving dose-dense chemotherapy regimens (n = 60; p < 0.01) and patients receiving adjuvant radiotherapy (n = 147, p < 0.01). In pre-menopausal patients, significant changes in CD4+ T cells subsets post-chemotherapy were observed. Further investigation, including long-term clinical outcomes, is needed to meaningfully improve long-term anti-tumour immunity.
- 21 October 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-10
Open AccessSustained lymphocyte decreases after treatment for early breast cancer
The role of adaptive immunity in long-term outcomes in early breast cancer is increasingly recognised. Standard (neo)adjuvant chemotherapy can have adverse effects on immune cells. We conducted a retrospective longitudinal study of full blood counts (FBC) of 200 patients receiving (neo)adjuvant chemotherapy for early breast cancer at a single institution. FBC results at four time points from pre-treatment to 12 months post-chemotherapy were analysed. Flow cytometry was performed for patients with matched pre- and post-chemotherapy peripheral blood mononuclear cell samples. A significant decrease in absolute lymphocyte count at 12 months post-chemotherapy was observed (p < 0.01), most pronounced in pre-menopausal patients (n = 73; p < 0.01), patients receiving dose-dense chemotherapy regimens (n = 60; p < 0.01) and patients receiving adjuvant radiotherapy (n = 147, p < 0.01). In pre-menopausal patients, significant changes in CD4+ T cells subsets post-chemotherapy were observed. Further investigation, including long-term clinical outcomes, is needed to meaningfully improve long-term anti-tumour immunity.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2− and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30% and the clinical benefit rate was 36%. A decline in PI3K pathway mutant circulating tumor DNA (ctDNA) levels from baseline to week 8 while on therapy was significantly associated with a partial response, clinical benefit, and improved progression-free-survival [HR 0.24; 95% confidence interval (CI), 0.083–0.67, P = 0.0065]. Detection of ESR1 mutations at baseline in plasma was also associated with clinical benefit and improved progression-free survival (HR 0.22; 95% CI, 0.078–0.60, P = 0.003).Significance:Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting.This article is highlighted in the In This Issue feature, p. 2007
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2− and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30% and the clinical benefit rate was 36%. A decline in PI3K pathway mutant circulating tumor DNA (ctDNA) levels from baseline to week 8 while on therapy was significantly associated with a partial response, clinical benefit, and improved progression-free-survival [HR 0.24; 95% confidence interval (CI), 0.083–0.67, P = 0.0065]. Detection of ESR1 mutations at baseline in plasma was also associated with clinical benefit and improved progression-free survival (HR 0.22; 95% CI, 0.078–0.60, P = 0.003).Significance:Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting.This article is highlighted in the In This Issue feature, p. 2007
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study